Compound ID | 3410
VE303
Synonym(s): VE-303 | VE 303
| Agent Type: | Indirect acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Corrects dysbiosis of the gut microbiota |
| Target Pathogen: | Active against Clostridioides difficile; indicated for C. difficile infection |
| Description: | Live biotherapeutic product containing 5 Clostridium cluster XIVa strains, 2 cluster IV strains, and 1 cluster XVII strain |
| Institute where first reported: | Vedanta Biosciences |
| Year first mentioned: | 2022 |
| Highest development stage: | Phase 2 |
| Development status: | Active |
| External links: | |
| Citation: | https://www.sciencedirect.com/science/article/pii/S1931312822001469?via%3Dihub |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.